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Abstract
Objective Dose optimization of TNF inhibitors in axial spondyloarthritis (axSpA) is attractive, but it is
unclear for which patients this approach might be appropriate.
Methods Seventy-one patients with axSpA, from six UK centres, were identified who had reduced
their dose of TNF inhibitor after being considered to be stable responders. All completed a question-
naire concerning their approach to and experience of dose reduction. Data on patient characteristics,
metrology and CRP were retrieved retrospectively from patient records.
Results Over 2 years of observation, 60 (84.5%) remained (REM) on reduced-dose medication and
11 (15.5%) reverted (REV) to the original dose. The overall mean dose reduction was 39% for REM
patients and 44% for REV patients. Both groups initially responded in a similar manner to treatment,
but the data showed a trend that younger women were more likely to revert. Neither BMI nor smoking
was associated with continued low-dose responsiveness. Eight of the 11 REV patients reverted by
6 months. None reached criteria of secondary drug failure, and all regained control after increasing
back to the original dose. Most patients in both groups reached the decision to reduce the dose jointly
with clinicians. A preference for taking the reduced dose was not associated with low-dose drug
survival.
Conclusion Many patients with axSpA remain well symptomatically after stepping down the dose of
TNF inhibitor, but young women are less likely to do well on a reduced dose. Dose reduction should
be one element of the management of patients with axSpA.
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Introduction
Several studies have shown that withdrawal of TNF in-
hibitor (TNFi) after a good response in patients with axial
spondyloarthritis (axSpA) results in relapse in the major-
ity of patients [1–3]. However, clinical experience indi-
cates that some patients with axSpA respond initially to
lower-dose treatment [4–6] and that some of those who
respond well to full-dose TNFi treatment are able to re-
duce the dose and remain symptomatically well, with
or without concurrent MTX [7–10]. Dose optimization is
attractive on cost and safety grounds, but a number of
important unresolved questions prevent its recommen-
dation; chief of these is whether the potential benefits of
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TNFi treatment, besides symptom control (prevention of
long-term structural damage and long-term functional
impairment), can be maintained at lower doses. Of equal
importance is the identification of patients who are
likely to do well on reduced-dose treatment, or even
treatment withdrawal, and those in whom such an ap-
proach has a high likelihood of failure. Dose reduction
carries the risk of disease flare; this may reflect inciden-
tal secondary failure of TNFi treatment [11, 12], but
experience of restarting full-dose treatment after treat-
ment dose reduction suggests that restoration of re-
sponse is usual.
In the absence of clear data to support such dose-
reduction strategies, dose reduction has occurred
largely on an ad hoc basis. Some patients have simply
chosen to use the minimum dose because of personal
preference, whereas some rheumatology units in the UK
have allowed dose reduction where patients have
expressed a preference. These changes need to be
seen in the context of limited compliance with TNFi dos-
ing reported in RA and psoriasis, ranging from 40% to
>80% [13, 14]. Such ad hoc changes allow only limited
conclusions to be drawn about the pros and cons of
dose reduction, but they might help to identify individu-
als in whom such strategies might be successful.
Complex therapeutic trials might eventually help to re-
solve these issues, whereas real-world observational
studies can help to provide some guidance to clinicians
and patients who need it now.
At six rheumatology units within the UK, patients with
axSpA who were noted to have reduced the dose of
TNFi medication after a good response were investi-
gated. The aim of the study was to explore patient- and
disease-associated factors predictive of long-term suc-
cess and failure of reducing the doses of TNFi medica-
tion over a 2-year period.
Methods
Seventy-one patients, from six UK centres, with a diag-
nosis of axSpA and fulfilling classification criteria for AS
(modified New York criteria [15]) or axSpA (Assessment
of SpondyloArthritis international Society [ASAS] criteria
[16]) and who had reduced their dose of TNFi, were
identified. All were considered to be stable responders
to TNFi; their responses fulfilled National Institute for
Health and Care Excellence criteria and were maintained
for 6 months by the time of dose reduction. Each was
observed for 2 years after dose reduction, with the
outcome of interest being the time to reversion to the
standard dose. No planned dose-reduction regimen was
used; patients either decided for themselves or were ad-
vised on an ad hoc basis by their treating clinicians.
After obtaining ethical approval, all patients, whether
now on reduced-dose treatment or having reverted to
full-dose treatment, were asked to complete a question-
naire. This asked about ethnicity, the way in which
dose-reduction decisions were taken, including the input
of health-care professionals, the confidence with which
patients took or accepted the decision, perceived
effects of dose reduction on symptoms, lifestyle, work
and sleep, effects on any associated conditions and any
changes in concurrent medication. All patients were also
asked to quantify cigarette smoking, past and present.
Data on age, height, weight and BMI, disease dura-
tion, duration and doses of TNFi treatment and
responses as measured by the BASDAI, BASFI and
BASMI over time were collected from departmental clini-
cal records. Each patient was assigned a random num-
ber, meaning that, after linkage of the two data sets,
analysis was carried out on anonymized data.
Thirty-seven patients were treated with adalimumab,
20 with etanercept, seven with infliximab and seven with
golimumab. All patients started treatment on standard
recommended doses and frequency of administration.
All patients were taking originator drugs at the time of
the study; none was receiving a biosimilar. The propor-
tion of dose reduction was calculated as a percentage,
in milligrams per month, of the original, standard dose.
For patients receiving infliximab, the percentage dose
reduction was calculated from the milligrams per kilo-
gram administered and the interval between infusions.
All patients completed BASDAI and BASFI question-
naires at each visit, with annual BASMI measurement.
CRP levels were measured frequently. Individuals who
continued to take reduced-dose treatment throughout
the observation period were designated remainers
(REM) and those who reverted to full-dose treatment
during it were designated reverters (REV). For REV
patients, the duration of reduced-dose treatment was
recorded. The mean dose reduction for each of the four
agents was 39% for adalimumab, 39% for etanercept,
26% for golimumab and 46% for infliximab. The overall
mean dose reduction was 39% for REM patients and
44% for REV patients.
Data were collected at six time points: (1) immediately
before starting TNFi therapy; (2) at the point of dose re-
duction; (3) at the point of reversion to full-dose
Key messages
. Of stable responders to TNF inhibitor, 84.5% remained on a mean 39% reduced-dose medication over 2 years of
observation.
. Younger axial spondyloarthritis patients and females were associated with risk of reversion to full-dose treatment.
. Dose reduction in axial spondyloarthritis should be part of dose-optimization strategies.
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treatment (REV only); (4) 6 months after dose reduction;
(5) 12 months after dose reduction; and (6) 24 months
after dose reduction. Time point 3 was notional, be-
cause reversion could occur at any point over the obser-
vation period.
The analysis of the time to reverting to the standard
dose was performed using survival analysis methods.
The length of follow-up was recorded only up to
24 months, meaning that only patients reverting within
the first 24 months were considered; those who reverted
after 24 months were considered not to have reverted.
Kaplan–Meier methods were used to plot the proportion
remaining on the low-dose over time and to quantify the
proportion at key time points in the follow-up period.
Patient factors associated with the time to reversion
were analysed using Cox regression.
Results
Of the 71 participants, 56 (78.9%) were male, aged
28–71 (mean 51.1) years, and 15 (21.1%) female, aged
24–71 (mean 49.9) years. Sixty-one were white, eight
were of South Asian origin and two were of other ethnic-
ity. Within the 24-month period, 60 (84.5%) patients
were REM and 11 (15.5%) were REV. The mean disease
duration in these two subgroups was 19.4 and
22.2 years, respectively. REM patients had taken TNFi
for a mean of 3.6 years compared with 1.8 years for REV
patients before dose reduction. Nine (16.1%) patients
had diagnosed IBD, 11 (19.6%) had psoriasis and 11
(19.6%) had previously had episodes of uveitis. Eight
(11.3%) were current smokers and 38 (53.5%) others
had smoked at some time (ever smokers); 25 (35.2%)
had never smoked. Fifty-four (76.1%) patients were
employed or self-employed, 3 (4.2%) were work-
disabled and 13 (18.3%) were retired.
Demographics, including work and associated co-
morbidities of the whole group, REM and REV patients
are demonstrated in Table 1. It can be seen that REM
and REV patients have broadly similar demographics.
Further analysis of age, sex, baseline BASDAI and CRP
are presented in Table 2.
Age was also associated with reversion (P¼0.05), but
the data suggested that there was not a consistent
trend with increasing age. Thus, to provide the best fit
for the data, it was necessary to include both linear and
squared terms for age, with the results being best inter-
preted graphically. Fig. 1 shows how the hazard ratio for
age changes with time. The risk of reverting to the low
dose is presented relative to a person of average age
(50 years). The graph suggests that the highest risk of
reverting was for the youngest subjects. The risk de-
creased with increasing age up to 50 years. For sub-
jects aged >60 years, there was an increased risk of
reverting with further increase in age. The results also
suggest a significant association between sex and the
time to reverting. Females were found to have a signifi-
cantly increased risk of reverting than males. The hazard
(or risk) of reverting at any time was more than three
times higher in females than males.
TABLE 1 Patient characteristics
Characteristic Total (n571) REM (n560) REV (n5 11)
Female, n (%) 15 (21.1) 10 (16.6) 5 (45.5)
Age, mean (range), years 50.5 (24–72) 51.2 (26–71) 46.8 (24–72)
BMI, mean (range), kg/m2 26.8 (19–37) 26.6 (19–37) 27.6 (24–35)
Duration of disease, mean (range), years 19.9 (6–41) 19.4 (6–41) 22.2 (15–31)
Duration of TNFi at dose reduction, mean (range), years 3.9 (0.3–10.9) 3.6 (0.3–10.9) 1.8 (1.9–9.3)
Baseline BASDAI – 6.2 5.7
Baseline CRP – 14.5 9.4
Ethnicity, n (%)
Caucasian 61 (85.9) 52 (86.7) 9 (81.8)
South Asian 8 (11.3) 6 (10) 2 (18.2)
Other 2 (2.8) 2 (3) 0 (0)
Co-morbidities, n (%)
Uveitis 11 (19.6) 9 (15) 2 (18.2)
Psoriasis 11 (19.6) 8 (13.3) 3 (27.3)
IBD 9 (16.1) 9 (15) 0 (0)
Work statusa, n (%)
Employed 35 (50) 28 (46.7) 7 (63.6)
Self-employed 19 (27.1) 17 (28.3) 2 (18.2)
Not working 16 (22.9) 14 (23.3) 2 (18.2)
Smoking status, n (%)
Current smoker 8 (11.3) 8 (13.3) 0 (0)
Ever smoker 38 (53.5) 33 (55) 5 (45.5)
Never smoker 25 (35.2) 19 (31.7) 6 (44.5)
aData missing from one patient. REM: remainers; REV: reverters.
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Graphical illustrations of the results for the total num-
ber of patients are shown in Supplementary Fig. S1,
available at Rheumatology Advances in Practice online,
and in Fig. 2. Statistical analysis showed no evidence
that either the BASDAI or CRP was associated with the
time to revert to the original dose.
Two REM patients reported worsening of co-morbidity
symptoms (one IBD, one psoriasis), but this did not lead
to reversion. No REV patients reported worsening of co-
morbidity symptoms.
The proportion of patients remaining on the original
dose over the study period is shown in the Kaplan–
Meier plot (Supplementary Fig. S1, available at
Rheumatology Advances in Practice online). It can be
seen that 8 of the 11 patients reverted by 6 months and
that 84% of patients remained on the low dose at
24 months.
Analyses of factors associated with time to revert to
standard dose indicated that females had a significantly
increased risk of reverting compared with males, with
the risk of reverting at any time being more than three
times higher (P¼0.04). This is illustrated in Fig. 2.
Neither the baseline BASDAI score nor the CRP
level at the initiation of TNFi treatment was associ-
ated with reversion. It can be seen in Fig. 3 that
both groups responded equally to treatment and
exhibited similar scores in all measures at dose re-
duction and 6 months. Fig. 3 also shows that scores
for REM patients then remained stable or decreased
over the observation period from dose reduction, with
mean BASDAI scores reduced from 2.4 to 2.0
(20.8%), mean BASFI scores reduced from 2.4 to 1.9
(16.6%), mean BASMI scores reduced from 3.5 to
3.3 (5.7%) and mean CRP scores decreased from 3.4
to 1.9 mg/dl (87.2%). The mean BASDAI scores of
REV patients from dose reduction to dose reversion
decreased from 1.6 to 1.2 (25%), but over this period
the mean BASFI scores increased from 2.2 to 2.5
FIG. 1 Risk of reverting to original dose by age
The results also suggest a significant association between sex and the time to reversion. Females were found to
have a significantly increased risk of reverting than males. The hazard (or risk) of reverting at any time was more than
three times higher in females than males. Statistical analysis provides no evidence that either the BASDAI or CRP
level was associated with the time to revert to the original dose. Two remain (REM) patients reported worsening of
co-morbidity symptoms (one IBD, one psoriasis), but this did not lead to reversion. No revert (REV) patients reported
worsening of co-morbidity symptoms. The proportion of patients remaining on the original dose over the study period
is shown in the Kaplan–Meier plot in Supplementary Fig. S1, available at Rheumatology Advances in Practice online.
TABLE 2 Regression analyses examining factors associated with time to revert to standard dose
Variable Category/term Hazard ratio (95% CI) P-value
Agea Linear term 0.94 (0.58, 1.48) 0.05
Squared term 1.38 (1.00, 1.91)
Sex Male 1 0.04
Female 3.44 (1.05, 11.3)
BASDAI (baseline) – 0.72 (0.43, 1.19) 0.20
CRP (baseline) – 1.02 (0.79, 1.31) 0.89
aHazard ratio is given for a 10-year increase in age.
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(13.6%), mean BASMI scores increased from 3.5 to
4.3 (22.8%) and mean CRP scores also increased
modestly from 3.4 to 4.4 mg/dl (29.4%).
Effect of dose reduction on work, convenience,
sleep and concomitant medication
It can be seen in Table 3 that most patients in both
groups reached the decision jointly with clinicians. Fifty-
one (85%) REM patients either preferred or were indif-
ferent about the decision to reduce the dose, but six
(10%) REM and seven (63.6%) REV patients did not pre-
fer reducing the dose. Preference for taking the reduced
dose was associated with success of the low-dose regi-
men. REV patients were more likely to increase pain
medication, including NSAIDs.
Discussion
Despite the small numbers, these findings suggest sig-
nals worthy of further data collection and analysis.
Principally, the study suggests that, amongst these se-
lected patients with axSpA, 84% continued to respond
well to TNFi treatment over 24 months in spite of a
mean dose reduction of 38%, but that age and sex are
associated with drug survival of reduced-dose TNFi regi-
mens. There are grounds for cautiously predicting that
older male patients with raised pre-treatment levels of
CRP who have achieved the National Institute for Health
and Care Excellence response to TNFi treatment for
6 months are likely to remain symptomatically controlled
after dose reduction of 39%. It might be that reducing
the dose after a longer period of stable response, per-
haps 12 months, would greatly reduce the risk of rever-
sion. It appears likely that patients who are confident
with the reduced-dose approach, whose decision has
been shared with the clinical team and for whom the
opportunity to revert is readily available are more likely
to remain well on reduced-dose treatment.
The patients in the present study were typical of UK
hospital axSpA populations, although the low prevalence
of women might reflect the lower proportion of patients
with non-radiographic axSpA receiving TNFi treatment
at the time of recruitment.
Notably, at the point of reversion, REV patients did
not reach BASDAI levels indicative of secondary drug
failure, and all of the REV patients regained control after
dose reversion. This was preceded by modest increases
in BASDAI, BASFI, BASMI and CRP levels; the worsen-
ing of symptoms but maintenance of low CRP levels
raises questions about the mechanisms underpinning
dose reversion. Lower CRP levels have been reported in
women with axSpA [17], but the explanation is unclear.
Unsurprisingly, REV patients took more analgesic medi-
cation than REM patients after dose reduction, com-
mensurate with worse symptoms.
In this small sample, 8 of the 11 REV patients reverted
within 6 months. REV patients had taken biologic treat-
ment for less time than REM patients, suggesting that
dose reversion is more likely early in TNFi treatment and
soon after dose reduction. It might be significant that all
responded symptomatically to increasing the dose. No
clear influence of smoking has been shown, with ap-
proximately half the patients in each group being ever
smokers and only a few being current smokers. The
lack of effect of smoking might be attributable to the
small sample size, but it is consistent with the findings
that smoking does not influence response to TNFi in
axSpA [18].
The patient’s view of dose reduction is clearly relevant to
the success of dose optimization; although this study is
small, some important issues have been identified. Most
patients in both groups made the dose-reduction decision
jointly with clinicians. More REV patients than REM
patients, however, expressed concern about the dose
FIG. 2 Kaplan–Meier plot of time to reversion to the original dose by sex
Neither baseline BASDAI score nor CRP level at the initiation of TNFi treatment was associated with reversion. It can
be seen that both groups responded equally to treatment and exhibited similar scores in all measures at dose reduc-
tion and 6 months.
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reduction, suggesting that being ill at ease with dose re-
duction might have influenced survival of low-dose treat-
ment in this group. Holmes et al. [19] reported that most
patients are interested in reducing the dose of TNFi but
that fear of flare and inability to access expert advice tem-
pered this enthusiasm. Hewlett et al. [20] also found that
patients with axSpA express anxiety about dose reduction
but that clear rationale, shared decision-making and con-
trol over the dose they take improves confidence. Our find-
ings would support these views.
In the present study, the process of shared decision-
making was not structured or formalized, and the deci-
sion to revert the dose was deliberately based on
patient choice. In further studies, it would be helpful to
draw up clear criteria for both dose reduction and dose
reversion. It would also be crucial to record the nature
of symptoms leading to dose reversion precisely, in or-
der that typical spondylitic symptoms could be sepa-
rated from fibromyalgic features, peripheral joint
symptoms and other symptoms that might be unrelated
FIG. 3 BASDAI, BASFI, BASMI and CRP levels from the time of dose reduction (time point 1) to 24 months (time
point 2)
It can also be seen that scores for remain (REM) patients were stable or decreased over the observation period from
dose reduction, with mean BASDAI scores reduced from 2.4 to 2.0 (20.8%), mean BASFI scores reduced from 2.4 to
1.9 (16.6%), mean BASMI scores reduced from 3.5 to 3.3 (5.7%) and mean CRP scores decreased from 3.4 to
1.9 mg/dl (87.2%). The mean BASDAI scores of reversion (REV) patients from dose reduction to dose reversion
decreased from 1.6 to 1.2 (25%), but over this period the mean BASFI scores increased from 2.2 to 2.5 (13.6%),
mean BASMI scores increased from 3.5 to 4.3 (22.8%) and mean CRP scores also increased modestly from 3.4 to
4.4 mg/dl (29.4%).
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to the primary disease. Likewise, it would be useful to
categorize patients before dose reduction with regard to
such features as anxiety that might influence readiness
to dose revert and to agree to set the decision in the
context of objective measures, including BASDAI and
CRP. This might help to establish whether the desire to
dose revert reflected disease activity or other factors.
Ultimately, patient choice might still be a sound basis
for dose changes in patients with axSpA receiving bio-
logic therapies. However, it is crucial that the patient is
informed in a precise and standardized way, that the
symptoms and measures of disease activity are pre-
cisely recorded at the time of decisions to change the
dose and that there is a justified relationship of trust be-
tween patient and condition.
In the treatment of axSpA, the treat-to-target ap-
proach [21, 22], with its uncertain targets but implication
of careful choice of first drug, dose escalation and drug
switching, is appealing but only part of the problem of
optimized treatment [23]. Keeping the target in mind but
maintaining it with minimal treatment is an integral part
of the approach. In RA, dose-reduction strategies are
frequently successful [24] and advocated in its treatment
[25, 26], but this is not currently the case with axSpA
[27].
In axSpA, therefore, it is important to define and un-
derstand both flare and relapse; both may reflect
changes in symptoms caused by either increased in-
flammatory activity or non-inflammatory mechanisms. It
is of interest that none of the REV patients reached cri-
teria for secondary drug failure. We agree with Edwards
et al. [28] that there is also a need to define the targets
of not only induction-phase full-dose remission (or low
disease activity) but also maintenance-phase remission
low disease activity in patients with axSpA.
Expenditure on medication and drug delivery was not
assessed in the present study, and absolute figures
would now be influenced heavily by the introduction of
biosimilars. However, it is worthy of comment that of the
60 REM patients, the mean dose reduction was 39%,
offering a substantial saving on medication costs. This is
clearly important in countries where drug costs are
borne by health services or insurers but might be
critically so in those where drug costs, hence access to
treatment, are borne by the patients themselves.
In this study, any individuals who explicitly did not
wish to take reduced-dose treatment were excluded.
Clearly, extended follow-up will be necessary, and the
likelihood of regaining low disease activity after dose re-
version needs to be clarified; however, in this study, all
REV patients regained symptom control and none
switched to an alternative biologic agent. It will be perti-
nent to consider further step-down approaches and to
develop further predictors of their success for both TNFi
and other biologic agents.
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